Rajesh Natarajan
Known title: DirectorCIK: 0001812674
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Bread Financial Holdings Faces Valuation Debate Ahead of Q3 Earnings Call. Analysts are debating Bread Financial’s valuation, with some suggesting the stock may still be undervalued despite a 231% run. TD Cowen and Barclays have adjusted price targets to $111 and $110, respectively, while the company has scheduled its Q3 2026 earnings call for Oct. 22. The stock sits near its 52‑week high and a support level of $107.22, and its low P/E of 6.8 and 3.09% dividend yield add to the discussion.
Transaction History
| HQY | ▲ Buy | Grant | 2,877 | $0 | 6/25/2026 | View on chart |
| BFH | ▲ Buy | Grant | 1,638 | — | 6/15/2026 | View on chart |
| HQY | ▲ Buy | Grant | 976 | $0 | 2/2/2026 | View on chart |
| HQY | ▲ Buy | Grant | 2,003 | $0 | 6/26/2025 | View on chart |
| BFH | ▲ Buy | Grant | 2,802 | — | 6/16/2025 | View on chart |
| HQY | ▲ Buy | Grant | 771 | $0 | 2/3/2025 | View on chart |
| HQY | ▲ Buy | Grant | 2,543 | $0 | 7/5/2024 | View on chart |
| BFH | ▲ Buy | Grant | 3,473 | — | 6/17/2024 | View on chart |
| HQY | ▲ Buy | Grant | 1,124 | $0 | 2/1/2024 | View on chart |
| HQY | ▲ Buy | Grant | 3,164 | $0 | 6/22/2023 | View on chart |
| BFH | ▲ Buy | Grant | 4,932 | — | 6/15/2023 | View on chart |
| HQY | ▲ Buy | Grant | 1,229 | $0 | 2/1/2023 | View on chart |
| HQY | ▲ Buy | Grant | 2,996 | $0 | 6/23/2022 | View on chart |
| BFH | ▲ Buy | Grant | 2,650 | — | 6/15/2022 | View on chart |
| BFH | ▲ Buy | Grant | 373 | — | 12/15/2021 | View on chart |
| BFH | ▲ Buy | Grant | 292 | — | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns
HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.
HealthEquity Appoints Moody's CFO to Board Amid AI Cash Concerns. HealthEquity has appointed Noémie Heuland, CFO of Moody's, to its board of directors. This governance move comes as market commentary highlights concerns regarding the company's cash position in the context of AI adoption. The stock is currently trading near its 52-week low, with an average analyst target price of $119.33.